Skip to Content

'
Amado J. Zurita-Saavedra, MD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1155 Pressler Street
Unit Number: 1374
Houston, TX 77030
Room Number: CPB7.3419
Phone: (713) 792-2830
Fax: (713) 745-1625

Education & Training

Degree-Granting Education

2001 Medical School, University of Barcelona, Barcelona, Spain, Pre Ph.D., Diploma of Advanced Studies (DEA)
1993 University of La Laguna, La Laguna, Santa Cruz de Tenerife, Spain, MD, Medicine

Board Certifications

7/2004 Educational Commission for Foreign Medical Graduates (ECFMG)
4/2000 Spanish Ministry of Health

Experience/Service

Academic Appointments

Clinical Fellow, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2/2006-3/2007
Postdoctoral Fellow, Department of Genitourinary Medical Oncology - Research, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 10/2001-1/2006
Instructor, Catalan Institute of Oncology, Barcelona, Spain, 5/2000-6/2001

Honors and Awards

2010 Young Investigators Award, Prostate Cancer Foundation, Washington, DC
2006 Participating in AACR/ASCO "Methods in Clinical Cancer Research" Workshop, Vail, CO
2002-2005 Research Training Award, Instituto de Salud Carlos III, Department of Health, Spain

Selected Publications

Peer-Reviewed Original Research Articles

1. Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Tapia EM, Zurita AJ, Aparicio A, Ravoori MK, Vazquez ES, Robinson DR, Wu YM, Cao X, Iyer MK, McKeehan W, Kundra V, Wang F, Troncoso P, Chinnaiyan AM, Logothetis CJ, Navone NM. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. (Research highlights on this article published in Nature Reviews Urology on September 23, 2014 and Cancer Discovery on September 25, 2014). Sci Transl Med 6(252):252ra122, 9/2014. PMID: 25186177.
2. Mehran R, Nilsson M, Khajavi M, Du Z, Cascone T, Wu HK, Cortes A, Xu L, Zurita A, Schier R, Riedel B, El-Zein R, Heymach JV. Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacy. Cancer Res 74(10):2731-41, 5/2014. e-Pub 3/2014. PMCID: PMC4024326.
3. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer. Clin Cancer Res 19(13):3621-30, 7/2013. e-Pub 5/2013. PMCID: PMC3699964.
4. Piao Y, Liang J, Holmes L, Zurita AJ, Henry V, Heymach JV, de Groot JF. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol 14(11):1379-92, 11/2012. e-Pub 9/2012. PMCID: PMC3480262.
5. Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 13(8):827-37, 8/2012. e-Pub 7/2012. PMID: 22759480.
6. Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, Zurita AJ, Rini BI, Sharma P, Atkins MB, Walker CL, Rathmell WK. State of the science: an update on renal cell carcinoma. Mol Cancer Res 10(7):859-80, 7/2012. e-Pub 5/2012. PMCID: PMC3399969.
7. Zurita AJ, George DJ, Shore ND, Liu G, Wilding G, Hutson TE, Kozloff M, Mathew P, Harmon CS, Wang SL, Chen I, Maneval EC, Logothetis CJ. Sunitinib in combination with docetaxel and prenisone in patients with metastatic, castration resistant prostate cancer: a phase I/II clinical trial. Ann Oncol 23(3):688-94, 3/2012. e-Pub 8/2011. PMID: 21821830.
8. Zurita AJ, Jonasch E, Wang X, Khajavi M, Yan S, Du DZ, Xu L, Herynk MH, McKee KS, Tran HT, Logothetis CJ, Tannir NM, Heymach JV. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 23(1):46-52, 1/2012. e-Pub 4/2011. PMCID: PMC3276320.
9. Gallick GE, Corn PG, Zurita AJ, Lin SH. Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer. Future Med Chem 4(1):107-19, 1/2012. PMCID: PMC3285098.
10. Bhatt RS, Zurita AJ, O'Neill A, Norden-Zfoni A, Zhang L, Wu HK, Wen PY, George D, Sukhatme VP, Atkins MB, Heymach JV. Increased mobilization of circulating endothelial progenitors in von Hippel Lindau disease and renal cell carcinoma. Br J Cancer 105(1):112-7, 6/28/2011. e-Pub 6/14/2011. PMCID: PMC3137404.
11. Karjalainen K, Jaalouk DE, Bueso-Ramos CE, Zurita AJ, Kuniyasu A, Eckhardt BL, Marini FC, Lichtiger B, O'Brien S, Kantarjian HM, Cortes JE, Koivunen E, Arap W, Pasqualini R. Targeting neuropilin-1 in human leukemia and lymphoma. Blood 117(3):920-7, 1/2011. e-Pub 11/2010. PMCID: PMC3298438.
12. Zurita AJ, Jonasch E, Wu HK, Tran HT, Heymach JV. Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. Cancer 115(10 Suppl):2346-54, 5/2009. PMID: 19402074.
13. Atkins MB, Bukowski RM, Escudier BJ, Figlin RA, Hudes GH, Kaelin WG, Linehan WM, McDermott DF, Mier JW, Pedrosa I, Rini BI, Signoretti S, Sosman JA, Teh BT, Wood CG, Zurita AJ, King L. Innovations and Challenges in Renal Cancer: Summary Statement From the Third Cambridge Conference. Cancer 115(10 Suppl):2247-51, 5/2009. PMCID: PMC2892290.
14. Mancuso P, Antoniotti P, Quarna J, Calleri A, Rabascio C, Tacchetti C, Braidotti P, Wu HK, Zurita AJ, Saronni L, Cheng JB, Shalinsky DR, Heymach JV, Bertolini F. Validation of a Standardized Method for Enumerating Circulating Endothelial Cells and Progenitors: Flow Cytometry and Molecular and Ultrastructural Analyses. Clin Cancer Res 15(1):267-73, 1/2009. PMID: 19118054.
15. Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin SH, Maity S, Navone NM. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest 118(8):2697-710, 8/2008. PMCID: PMC2447924.
16. Chu K, Cheng CJ, Ye X, Lee YC, Zurita AJ, Chen DT, Yu-Lee LY, Zhang S, Yeh ET, Hu MC, Logothetis CJ, Lin SH. Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res 6(8):1259-67, 8/2008. PMCID: PMC2643879.
17. Ozawa MG, Zurita AJ, Dias-Neto E, Nunes DN, Sidman RL, Gelovani JG, Arap W, Pasqualini R. Beyond receptor expression levels: the relevance of target accessibility in ligand-directed pharmacodelivery systems. Trends Cardiovasc Med 18(4):126-32, 5/2008. PMID: 18555185.
18. Cardó-Vila M, Zurita AJ, Giordano RJ, Sun J, Rangel R, Guzman-Rojas L, Anobom CD, Valente AP, Almeida FC, Lahdenranta J, Kolonin MG, Arap W, Pasqualini R. A Ligand Peptide Motif Selected from a Cancer Patient Is a Receptor-Interacting Site within Human Interleukin-11. PLoS One 3(10):e3452. doi:10.1371/journal.pone.0003452, 2008. e-Pub 10/2008. PMCID: PMC2565473.
19. Kolonin MG, Bover L, Sun J, Zurita AJ, Do KA, Lahdenranta J, Cardó-Vila M, Giordano RJ, Jaalouk DE, Ozawa MG, Moya CA, Souza GR, Staquicini FI, Kunyiasu A, Scudiero DA, Holbeck SL, Sausville EA, Arap W, Pasqualini R. Ligand-Directed Surface Profiling of Human Cancer Cells with Combinatorial Peptide Libraries. Cancer Res 66(1):34-40, 1/2006. PMID: 16397212.
20. Chen L, Zurita AJ, Ardelt PU, Giordano RJ, Arap W, Pasqualini R. Design and validation of a bifunctional ligand display system for receptor targeting. Chem Biol 11(8):1081-91, 8/2004. PMID: 15324809.
21. Zurita AJ, Troncoso P, Cardó-Vila M, Logothetis CJ, Pasqualini R, Arap W. Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res 64(2):435-9, 1/2004. PMID: 14744752.
22. Diestra JE, Condom E, Del Muro XG, Scheffer GL, Pérez J, Zurita AJ, Muñoz-Seguí J, Vigués F, Scheper RJ, Capellá G, Germà-Lluch JR, Izquierdo MA. Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications. J Urol 170(4 Pt 1):1383-87, 10/2003. PMID: 14501774.
23. Zurita AJ, Diestra JE, Condom E, García del Muro X, Scheffer GL, Scheper RJ, Pérez J, Germà-Lluch JR, Izquierdo MA. Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours. Br J Cancer 88(6):879-86, 3/2003. PMCID: PMC2377094.
24. Salar A, Carratalà J, Zurita A, González-Barca E, Grañena A. Bacteremia caused by CDC Group IV c-2 in a patient with acute leukemia. Haematologica 83(7):670-72, 7/1998. PMID: 9718879.
25. Capdevila O, Zurita A, Domingo E, Corbella X, Alcaide F, Monfort JL, Fernández-Viladrich P. Multiple cranial osteolytic lesions due to Mycobacterium kansasii in a patient with AIDS. Scand J Infect Dis 30(3):305-6, 1998. PMID: 9790143.

Invited Articles

1. Hernandez-Yanez M, Heymach JV, Zurita AJ. Circulating biomarkers in advanced renal cell carcinoma: clinical applications. Curr Oncol Rep 14(3):221-9, 6/2012. e-Pub 3/2012. PMCID: PMC3872150.
2. Mateo J, Heymach JV, Zurita AJ. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook. Mol Diagn Ther 16(3):151-61, 6/2012. PMCID: PMC3872147.
3. Zurita AJ, Arap W, Pasqualini R. Mapping tumor vascular diversity by screening phage display libraries. Journal Controlled Release 91(1-2):183-86, 8/2003. PMID: 12932650.

Editorials

1. Zurita AJ. A second opportunity to come for anti-angiogenics in prostate cancer? Transl Cancer Res. In Press.

Abstracts

1. Zurita AJ, Carlsson A, Luttgen MS, Bethel K, Logothetis C, Hicks J, Kuhn P,. High-Definition Single Cell Analysis (HD-SCA) of Prostate Cancer (PCa) Cells in Matched Bone Marrow and Blood from Patients. ESMO 2014 Congress Abstract Book (#7223). In Press.
2. Corn PG, Tu S, Zurita AJ, Pagliaro LC, Logothetis C, Aparicio A. A randomized phase I/II study to examine the contribution of carboplatin to cabazitaxel for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) with and without anaplastic features. J Clin Oncol 32 (#148), 2014.
3. Yetil A, Barry ST, Heymach JV, Zurita AJ. Myeloid Cell and Plasma Cytokine and Angiogenic Factor (CAF) Dynamics in Association with Response to VEGF-Receptor Inhibitors Cediranib and Sunitinib. 2014 Annual AACR Meeting (# 29) (#29), 2014.
4. Zurita AJ, Liu Y, Gagnon RC, D'Amelio A, Tran HT, Bartlett-Pandite AN, Heymach J. Osteopontin (OPN), TIMP-1, and interleukin (IL)-6 as prognostic (prog) for overall survival (OS) and independent from clinical criteria in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 32 (#4582), 2014.
5. Zurita AJ, Pagliaro LC, Troncoso P, Davis JW. Presurgical axitinib and androgen deprivation therapy (ADT) in prostate cancer (PCa) patients (pts) presenting with lymph node (LN) metastasis. J Clin Oncol 32 (#TPS5109), 2014.
6. Bilen MA, Hess KR, Aparicio A, Kim J, Zurita AJ, Pagliaro LC, Araujo JC, Corn PG, Atkinson BJ, Tannir NM, Sharma P, Lin SH, Logothetis C, Tu SM. Sipuleucel-T cellular immunotherapy: Clinical predictors of survival in patients with castration-resistant prostate cancer (CRPC). J Clin Oncol 32 (#e16046), 2014.
7. Yetil A, Jonasch E, Wang X, Wood CG, Matin SF, Tran HT, Tannir NM, Heymach JV, Zurita AJ. Plasma Cytokines and Angiogenic Factors Associated with Survival and Clinical Benefit from Bevacizumab in a Phase II Presurgical Study of Metastatic Renal Cell Carcinoma Patients. 2013 Annual AACR Meeting (#4645) (#4645), 4/2013.
8. Zurita AJ, Bischoff FZ, Gorlov I, Mayer JA, Pircher TJ, Mikolajczyk S, Logothetis C, Lin SH. Cadherin-11 (Cad11) for detection of epithelial-mesenchymal transition (EMT) in circulating prostate cancer (PCa) cells. J Clin Oncol 31 (#e22047), 2013.
9. Corn PG, Varkaris A, Li Ning Tapia EM, Araujo JC, Aparicio A, Tu SM, Zurita AJ, Efstathiou E, Qiao W, Wen S, Gallick GE, Logothetis C. Modulation of soluble c-Met, bone turnover markers, angiogenic factors, and c-Met in men with mCRPC treated with cabozantinib. J Clin Oncol 31 (#58), 2013.
10. Heath EI, Mannuel HD, Liu G, Lara P, Monk JP, Flaig TW, Zurita AJ, Vaishampayan UN, Stella PJ, Smith DW, Kobson K, Hussain A, Al-Janadi A, Ivy P, Heilbrun LK. Randomized phase II trial of docetaxel (Doc) and prednisone (Pred) with or without AZD2171 (cediranib), in chemotherapy-naive, metastatic castrate-resistant prostate cancer (mCRPC) (NCI 7451). J Clin Oncol 31 (#38), 2013.
11. Dayyani F, Nogueras-Gonzalez GM, Slack R, Millikan RE, Zurita AJ, Araujo JC, Gallick GE, Logothetis C, Corn PG. Serum insulin to predict time to castration-resistant progression and overall survival in metastatic androgen-dependent prostate cancer (mADPCa). J Clin Oncol 31 (#e16038), 2013.
12. Tran HT, Liu Y, Lin Y, Zurita Saavadra AJ, Baker-Neblett KL, VEG105192 Team and investigators, Pandite LN, Heymach JV. Dynamic changes in plasma osteopontin as a markers of tumor response in metastatic renal cell carcinoma (RCC) patients treated with pazopanib. Ann Oncol 23(9):ix258-ix293 (#833P), 10/2012.
13. Zurita-Saavedra A, Liu Y, Lin Y, Tran HT, VEG105192 Team and investigators, Pandite LN, Heymach JV. Multivariate analysis of cytokines and angiogenic factors (CAFS) and established prognostic parameters in metastatic renal cell carcinoma (mRCC) patients (PTS) receiving pazopanib or placebo. Ann Oncol 23(9):ix261 (#791PD), 9/2012.
14. Efstathiou E, Davis JW, Troncoso P, Titus MA, Hoang A, Wen S, Zurita AJ, Tran N, Molina A, Logothetis C. Cytoreduction and androgen signaling modulation by abiraterone acetate (AA) plus leuprolide acetate (LHRHa) versus LHRHa in localized high-risk prostate cancer (PCa): Preliminary results of a randomized preoperative study. J Clin Oncol 30 (#4556), 2012.
15. Nieto Y, Tannir NM, Tu S, Jones RB, Zurita AJ, Aparicio A, Bassett R, Margolin KA, Holmberg L, Champlin RE, Pagliaro LC,. Phase II trial of vevacizumab (BEV)/high-dose chemotherapy (HDC) for refractory germ-cell tumors (GCT). J Clin Oncol 30 (#4533), 2012.
16. Zurita AJ, Khajavi M, Wang X, Wood CG, Matin SF, Fiorentino S, McKee KS, Tran HT, Heymach J, Jonasch E. Plasma cytokines and angiogenic factors (CAFs) associated with risk of recurrence and tumor dependence in patients (pts) with nonmetastatic renal cell carcinoma (RCC). J Clin Oncol 30 (#383), 2012.
17. Karjalainen K, Jaalouk DE, Bueso-Ramos CE, Zurita AJ, Kuiyasu A, Eckhardt BL, Marini FC, Lichtiger B, O'Brien S, Kantarjian HM, Cortes JE, Koivunen E, Arap W, Pasqualini R. Therapeutic targeting of leukemia and lymphoma with a neuropilin-1 binding pro-apoptotic peptide. 2012 Annual AACR Meeting (#2903) (#2903), 2012.
18. Aparicio A, Harzstark AL, Lin E, Corn PC, Araujo JC, Tu S, Pagliaro LC, Millikan RE, Arap W, Kim J, Ryan CJ, Zurita AJ, Tannir NM, Lin AM, Small J, Mathew P, Jones DM, Troncoso P, Thall PF, Logothetis C,. Characterization of the anaplastic prostate carcinomas: A prospective two-stage phase II trial of frontline carboplatin and docetaxel (CD) and salvage etoposide and cisplatin (EP). J Clin Oncol 29, 2/2011.
19. Liu Y, Tran T, Lin Y, Martin A, Zurita A, Sternberg CN, Amado RG, Pandite LN, Heymach J,. Circulating baseline plasma cytokines and angiogenic factors (CAF) as markers of tumor burden and therapeutic response in a phase III study of pazopanib for metastatic renal cell carcinoma (mRCC). J Clin Oncol 29 (#4553), 2/2011.
20. Zurita AJ, Heymach J, Khajavi M, Tye L, Huang X, Kulke M, Lenz H, Meropol NJ, Carley W, DePrimo SE, Harmon CS,. Circulating protein and cellular biomarkers of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 29 (#4079), 2/2011.
21. Zurita AJ, Khajavi M, Mulders P, Yan S, McKee KS, Tran HT, Pike L, Mookerjee B, Jurgensmeier J, Heymach J,. Cytokine and angiogenic factor (CAF) profiling for identification of markers associated with response to cediranib in metastatic renal cell carcinoma (mRCC). J Clin Oncol 29 (#362), 2/2011.
22. George DJ, Halabi S, Zurita AJ, Creel P, Mundy K, Turnbull JD, Yenser Wood SE, Armstrong AJ, Varley RJ, Madden J, Moul JW. Investigator -initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer Clinical Trials Consortium. J Clin Oncol 29 (#4664), 2/2011.
23. Zurita AJ, Ward JF, Araujo JC, Pettaway CA, Dieringer P, Wang X, Troncoso P, Logothetis C. Neoadjuvant trial of sunitinib malate and androgen ablation (ADT) in patients with localized prostate cancer (PCa) at high risk for recurrence. J Clin Oncol 29 (#143), 2/2011.
24. Liu Y, Tran HT, Lin Y, Martin A, Zurita AJ, Sternberg CN, Amado RG, Pandite LN, Heymach J. Plasma cytokine and angiogenic factors (CAFs) predictive of clinical benefit and prognosis in patients (Pts) with advanced or metastatic renal cell cancer (mCRR) treated in phase III trials of pazopanib (PAZO). J Clin Oncol 29 (#334), 2/2011.
25. Pagliaro LC, Zurita AJ, Araujo JC, Ward JF, Davis JW, Pettaway CA, Tu S, Kim J, Dieringer P, Logothetis C, Pister LL. Presurgical docetaxel (Doc) and androgen deprivation therapy (ADT) in lymph node-positive prostate cancer (PCa). J Clin Oncol 29 (#4619), 2/2011.
26. Tran HT, Liu Y, Lin Y, Martin A, Baker KL, Fritsche HA, Zurita AJ, Pandite L, Heymach J. Use of a multiplatform analysis of plasma cytokines and angiogenic factors (CAFs) to identify baseline CAFs associated with pazopanib response and tumor burden in renal cell carcinoma (RCC) patients. J Clin Oncol 28(15S) (#4522), 6/2010.
27. Zurita AJ, Khajavi M, Logothetis CJ, Lin SH. Clinical Applications for osteoblast-cadherin in prostate cancer bone metastasis. Prostate Cancer Foundation Annual Scientific Retreat (PCF) Sept 2009, Incline Village, NV, 9/2009.
28. Heymach JV, Jonasch E, Wang X, Du DZ, Yan S, Xu L, Herynk MH, McKee KS, Tran HT, Tannir NM, Zurita AJ. A cytokine and angiogenic factor (CAF) plasma signature for selection of sorafenib (SR) therapy in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 27(15S) (#5114), 5/2009.
29. Zurita AJ, Liu G, Hutson T, Kozloff M, Shore N, Wilding G, Logothetis CJ, Chen I, Chow Maneval E, George D. Sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone-refractory prostate cancer (mHRPC). 45th Annual Meeting of the American Society of Clinical Oncology (ASCO); Poster (#5166),, 5/2009.
30. Wu HK, Jonasch E, Wood C, Tannir NM, Matin S, McKee KS, Heymach JV, Zurita AJ. Circulating endothelial cells (CEC) and progenitors (CEP) and VEGFR-1-expressing monocytes as biomarkers for patients (pts) with renal cell carcinoma (RCC). 2009 Annual AACR Meeting (#LB-268) (#LB-268), 2009.
31. Zurita AJ, Wu HK, Lin E, Kulke M, Tye L, Bello CL, DePrimo SE, McKee KS, Heymach JV. Sunitinib (SU) affects specific peripheral blood mononuclear cell subpopulations (PBMC) and circulating endothelial cells (CEC) in patients (pts) with neuroendocrine tumors (NET): correlation with plasma proteins and pharmacokinetics. 2009 Annual AACR Meeting (#LB-284) (#LB-284), 2009.
32. Tannir NM, Zurita AJ, Heymach JV, Tran HT, Pagilaro LC, Corn P, Aparicio AM, Ashe R, Wright JJ, Jonasch E. A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa: Clinical results and biomarker analysis. J Clin Oncol 26 (#5093), 2008.
33. Li ZG, Navone N, Yang J, Liu J, Mathew P, Starbuck M, Zurita A, Sikes C, Multani A, Efstathiou E, Lopez A, Wang J, Fanning T, Prieto V, Kundra V, Troncoso P, Raymond A, Lin SH, Vazquez E. Androgen receptor-negative human prostate cancer cells induce osteogenesis through FGF9-mediated mechanisms. 2008 Annual AACR Meeting (#1612) (#1612), 2008.
34. Zurita A, Jonasch E, Du D, Yan S, Wang X, Xu L, Herynk M, McKee K, Tran H, Tannir N, Heymach J. Cytokine and angiogenic factor (CAF) profiling for prediction of outcome to first line sorafenib (SR) versus SR plus low-dose interferon-{alpha} (IFN{alpha}) in patients with advanced renal cell carcinoma (mRCC). 2008 Annual AACR Meeting (#LB-218) (#LB-218), 2008.
35. Mancuso P, Antoniotti P, Quarna J, Calleri A, Rabascio C, Tacchetti C, Braidotti P, Wu HK, Zurita A, Saronni L, Cheng J, Shalinsky D, Heymach J, Bertolini F. Molecular, electron-microscopic, inter-laboratory and clinical validation of a novel standardized flow cytometric method for the enumeration of circulating endothelial cells and progenitors. 2008 Annual AACR Meeting (#5855) (#5855), 2008.
36. Zurita AJ, Ward JF, Araujo JC, Pettaway CA, Pisters LL, Dieringer P, Troncoso P, Logothetis CJ. Presurgical sunitinib malate and androgen ablation in patients with localized prostate cancer at high risk for recurrence. J Clin Oncol 26 (#16004), 2008.
37. George DJ, Liu G, Wilding G, Hutson TE, Chen I, Chow Maneval E, Logothetis C, Zurita AJ. Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refactory prostate cancer (mHRPC)-preliminary results. J Clin Oncol 26 (#5131), 2008.
38. Zurita AJ, Shore ND, Kozloff MF, Ryan CW, Beer TM, Maneval EC, Chen I, Logothetis CJ. A phase I/II study of sunitinib in combination with docetaxel (dcx) and prednisone (pdn) in patients with metastatic castrate-resistant prostate cancer (mCRPC). ECCO 14, 9/2007.
39. Zurita AJ, Shore ND, Kozloff MF, Ryan CW, Beer TM, Maneval EC, Chen I, Logothetis CJ. Phase I Study of Sunitinib in combination with Docetaxel and Prednisone in Metastatic Castrate-Resistant Prostate Cancer (CRPC). Department of Defense Prostate Cancer Research Program and Technical Planning Committee for the Innovative Minds in Prostate Cancer Today (IMPaCT); Presentation, 9/2007.
40. Zurita AJ, Shore ND, Kozloff MF, Ryan CW, Beer TW, Chow-Maneval E, Chen I, Logothetis CJ. Distinct patterns of PSA modulation by single-agent sunitinib before combination with docetaxel and prednisone in patients with metastatic castrate-resistant prostate cancer (CRPCa). J Clin Oncol 25(18S) (#5134), 6/2007.
41. Zurita AJ, Shore ND, Kozloff MF, Ryan CW, Beer TW, Chow-Maneval E, Chen I, Logothetis CJ. Phase I study of sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone refractory prostate cancer (mHRPC). Prostate Cancer Symposium ASCO (#230), 2/2007.
42. Zurita A, Wu HK, Kulke M, Tye L, Bello C, PePrimo S, McKee K, Heymach J. Sunitinib affects specific subpopulations of peripheral blood monocytic cells in patients with unresectable neuroendocrine tumor (NET): an 8-color flow cytometry analysis. 2007 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics (#C162) (#C162), 2007.
43. Jaalouk DE, Kuniyasu A, Zurita A, Beran M, Arap W, Pasqualini R. Targeting of cell surface receptors in leukemia with ligand-directed pro-apoptotic peptides. 14th Annual SPORE Investigators’ Workshop, 7/2005.
44. Zurita AJ, Hajitou A, Cardó-Vila M, Troncoso P, Logothetis CJ, Pasqualini R, Arap W. Preclinical development of an interleukin-11 receptor-targeted pro-apoptotic peptide against advanced prostate cancer. 40th Annual Meeting of the American Society of Clinical Oncology; Proc ASCO (#3190), 2004.
45. Bover LC, Holbeck S, Scudiero DA, Zurita AJ, Sausville E, Pasqualini R, Arap W. Targeting the NCI 60-cell panel by biopanning and rapid analysis of selective interactive ligands. AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics; Poster, 11/2003.
46. Zurita AJ, Troncoso P, Logothetis CJ, Pasqualini R, Arap W. A ligand peptide with potential for targeting prostate cancer metastatic to the bone marrow. 94th Annual Meeting of the American Association for Cancer Research; Proc AACR 44 (#1659), 7/2003.
47. Gil M, Majem M, Mora J, Perez J, Ponce J, Izquierdo MA, Zurita A, Germà JR. Radioimmunoscintigraphy with indium-111-labeled monoclonal antibody b72.3 in epithelial ovarian cancer. European Cancer Conference (ECCO 12); Eur J Cancer Sppls 1(5):S310, 2003.

Book Chapters

1. Zurita AJ, Ward JF, Kim J. Targeted Therapy in Prostate Cancer. In: Targeted Therapy in Cancer. Ed(s) R Kurzrock, M Markman. The Humana Press, USA, 289-304, 2008.
2. Zurita AJ, Wu HK, Heymach JV. Blood-Based Biomarkers for VEGF inhibitors. In: Antiangiogenic Cancer Therapy. Ed(s) DW Davis, RS Herbst, JL Abbruzzese. Taylor and Francis Group, LLC Authors, 517-31, 2007.
3. Zurita AJ, Arap W, Pasqualini R. Molecular Characterization of the Endothelium: A Phage Display Perspective The Endothelium: a phage display perspective the endothelium. In: A Comprehensive Reference: The Endothelial Cell as Imput-Ouptut Device/Output/Proteome. Ed(s) W.C. Aird. Marcel Dekker, Inc., 898-908, 2007.

Letters to the Editor

1. Zurita Saavedra AJ, Navarro Garcia M, Español I, Fernández Ortega A. UFT-induced haemolytic anaemia. Cancer Chemotherapy Pharmacology 47(3):280-81, 3/2001. PMID: 11320674.

Grant & Contract Support

Title: PCF-Movember Gap
Funding Source: Prostate Cancer Foundation
Role: Principal Investigator
Duration: 1/1/2014 - 12/31/2014
 
Title: Modulation of Anti-Angiogenic Resistance in Renal Cell Carcinoma: Targeting JAK/STAT/HIF
Funding Source: Kidney Cancer Pilot Project Program
Role: Co-Principal Investigator
Duration: 5/7/2013 - 5/6/2014
 
Title: 8-Chloroadenosine Inhibits Growth of Renal Cell Cancer through AMPK Activation and MTOR Pathway Suppression
Funding Source: MDACC Institutional Research Grant
Role: Principal Investigator
Duration: 2/1/2013 - 1/31/2015
 
Title: Clinical applications for cadherin-11 in prostate cancer bone metastasis
Funding Source: Prostate Cancer Foundation
Role: 2010 Young Investigator Award
Duration: 4/16/2010 - 4/15/2013
 
Title: Circulating osteoblast lineage cells as a new biomarker in prostate cancer bone metastasis
Funding Source: MDACC Institutional Research Grant
Role: Principal Investigator
Duration: 7/1/2009 - 6/30/2011
 
Title: Circulating biomarkers of antiangiogenic therapy: tumor vs. host dependence and determinants of resistance
Funding Source: AstraZeneca-MD Anderson Strategic Alliance
Role: Principal Investigator
Duration: 10/1/2008 - 9/1/2013
 
Title: Role of OB-Cadherin in Prostate Cancer Bone Metastasis
Funding Source: American Society of Clinical Oncology
Role: Principal Investigator
Duration: 7/1/2007 - 3/31/2009
 
Title: Osteoblast Cadherin (OB-Cadherin) for the Prediction and Prevention of Bone Metastasis
Funding Source: Prostate Cancer Foundation
Role: Co-Investigator
Principal Investigator: Sue-Hwa Lin
Duration: 5/1/2007 - 4/30/2008
 
Title: Developing Osteoblast Cadherin (Ob-Cadherin) as a biomarker and therapeutic target in prostate cancer bone metastasis
Funding Source: NIH/NCRR
Role: K12 Scholar
Principal Investigator: Frank Arnett
Duration: 8/30/2006 - 6/30/2011
 
Title: A Phase II Neoadjuvant Trial of Sunitinib Malate (SU011248) Plus Hormonal Ablation for Patients Who Have High Risk Localized Prostate Cancer and Will Undergo Prostatectomy
Funding Source: Pfizer
Role: Principal Investigator
Duration: 3/27/2006 - 3/31/2011

Last updated: 11/11/2014